CN104774860A - 适于转化细胞的构建体、系统及其应用 - Google Patents
适于转化细胞的构建体、系统及其应用 Download PDFInfo
- Publication number
- CN104774860A CN104774860A CN201410017168.3A CN201410017168A CN104774860A CN 104774860 A CN104774860 A CN 104774860A CN 201410017168 A CN201410017168 A CN 201410017168A CN 104774860 A CN104774860 A CN 104774860A
- Authority
- CN
- China
- Prior art keywords
- construct
- sequence
- transformant
- optionally
- promotor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010276 construction Methods 0.000 title abstract description 10
- 230000001131 transforming effect Effects 0.000 title abstract 5
- 108091033409 CRISPR Proteins 0.000 claims abstract description 63
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 108091028113 Trans-activating crRNA Proteins 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 10
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 10
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims description 8
- 102100026280 Cryptochrome-2 Human genes 0.000 claims description 7
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims description 7
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 7
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 claims description 7
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 claims description 7
- 101100236423 Oryza sativa subsp. japonica MADS3 gene Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 101150072950 BRCA1 gene Proteins 0.000 claims description 5
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 4
- 101150059079 EBNA1 gene Proteins 0.000 claims description 4
- 101150048453 MSTN gene Proteins 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 74
- 210000004962 mammalian cell Anatomy 0.000 abstract description 12
- 238000010008 shearing Methods 0.000 abstract description 7
- 239000003550 marker Substances 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical group 0.000 abstract description 2
- 238000012797 qualification Methods 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 20
- 238000012216 screening Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000001890 transfection Methods 0.000 description 9
- 238000010354 CRISPR gene editing Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 101100228884 Arabidopsis thaliana GHR1 gene Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108050006583 Growth/differentiation factor 8 Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 101100228739 Danio rerio mstnb gene Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101100437866 Mus musculus Brca1 gene Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100448395 Sus scrofa GHR gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Abstract
Description
基因特异位点 | 序列(5`-3`,SEQ ID NO:) |
CRY2-CRL1 | ACCGTGGCGAGAGTTCTTCTACAG(3) |
CRY2-CRR1 | AAAACTGTAGAAGAACTCTCGCCA(4) |
CRY2-CRL2 | ACCGTGGCCTGCTTCCTCACGCGG(5) |
CRY2-CRR2 | AAAACCGCGTGAGGAAGCAGGCCA(6) |
CRY2-CRL3 | ACCGCGGATTTCAGCGTGAATGCG(7) |
CRY2-CRR3 | AAAACGCATTCACGCTGAAATCCG(8) |
IL2RG-CRL1 | ACCGGGGGTGGGACTGAACCCGAG(9) |
IL2RG-CRR1 | AAAACTCGGGTTCAGTCCCACCCC(10) |
IL2RG-CRL2 | ACCGATGATAAAGTCCAGGAGTGG(11) |
IL2RG-CRR2 | AAAACCACTCCTGGACTTTATCAT(12) |
IL2RG-CRL3 | ACCGGCCACTATCTATTCTCTGAG(13) |
IL2RG-CRR3 | AAAACTCAGAGAATAGATAGTGGC(14) |
RAG1-CRL1 | ACCGAAAAGCAGGATTCCTCCGAG(15) |
RAG1-CRR1 | AAAACTCGGAGGAATCCTGCTTTT(16) |
RAG1-CRL2 | ACCGGAATTCTTTCAACACCACTG(17) |
RAG1-CRR2 | AAAACAGTGGTGTTGAAAGAATTC(18) |
RAG1-CRL3 | ACCGTAAAACCCAAGTCCTTTTAG(19) |
RAG1-CRR3 | AAAACTAAAAGGACTTGGGTTTTA(20) |
BRCA1-CRL1 | ACCGATTATTCTGAAGACCATTCG(21) |
BRCA1-CRR1 | AAAACGAATGGTCTTCAGAATAAT(22) |
BRCA1-CRL2 | ACCGGTCAGGGAAATAGGAGGTAG(23) |
BRCA1-CRR2 | AAAACTACCTCCTATTTCCCTGAC(24) |
BRCA1-CRL3 | ACCGGAGGTATGGTTTATGAGTAG(25) |
BRCA1-CRR3 | AAAACTACTCATAAACCATACCTC(26) |
BRCA1-CRL4 | ACCGTTTTAGTTCTTCTACCTAGG(27) |
BRCA1-CRR4 | AAAACCTAGGTAGAAGAACTAAAA(28) |
BRCA1-CRL5 | ACCGTACTTTGGTTTACTTTTAAG(29) |
BRCA1-CRR5 | AAAACTTAAAAGTAAACCAAAGTA(30) |
BRCA1-CRL6 | ACCGTTCTCATATCCAAAAATACG(31) |
BRCA1-CRR6 | AAAACGTATTTTTGGATATGAGAA(32) |
MSTN-CRL1 | ACCGCTTCAAAATCCACAGTTAGAG(33) |
MSTN-CRR1 | AAAACTCTAACTGTGGATTTTGAAG(34) |
MSTN-CRL2 | ACCGGATTTTGAAGCTTTTGGATGG(35) |
MSTN-CRR2 | AAAACCATCCAAAAGCTTCAAAATC(36) |
MSTN-CRL3 | ACCGGTGCACAAGATGAGTGTGAGG(37) |
MSTN-CRR3 | AAAACCTCACACTCATCTTGTGCAC(38) |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410017168.3A CN104774860B (zh) | 2014-01-14 | 2014-01-14 | 适于转化细胞的构建体、系统及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410017168.3A CN104774860B (zh) | 2014-01-14 | 2014-01-14 | 适于转化细胞的构建体、系统及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104774860A true CN104774860A (zh) | 2015-07-15 |
CN104774860B CN104774860B (zh) | 2018-07-17 |
Family
ID=53616630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410017168.3A Expired - Fee Related CN104774860B (zh) | 2014-01-14 | 2014-01-14 | 适于转化细胞的构建体、系统及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104774860B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112522309A (zh) * | 2020-09-04 | 2021-03-19 | 南京启真基因工程有限公司 | 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒 |
-
2014
- 2014-01-14 CN CN201410017168.3A patent/CN104774860B/zh not_active Expired - Fee Related
Non-Patent Citations (7)
Title |
---|
HERITABLE GENE-TARGETING WITH GRNA/CAS9 IN RATS: "Xinli Hu et al.", 《CELL RESEARCH》 * |
LE CONG ET AL.: "Multiplex Genome Engineering Using CRISPR/Cas Systems", 《SCIENCE》 * |
LEI S. QI ET AL.: "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression", 《CELL》 * |
NANNAN CHANG ET AL.: "Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos", 《CELL RESEARCH》 * |
PRASHANT MALI ET AL.: "RNA-Guided Human Genome Engineering via Cas9", 《SCIENCE》 * |
SHU KONDO AND RYU UEDA: "Highly Improved Gene Targeting by Germline-Specific Cas9 Expression in Drosophila", 《GENETICS》 * |
WATARU FUJII ET AL.: "Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease", 《NUCLEIC ACIDS RESEARCH》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112522309A (zh) * | 2020-09-04 | 2021-03-19 | 南京启真基因工程有限公司 | 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒 |
CN112522309B (zh) * | 2020-09-04 | 2023-10-13 | 南京启真基因工程有限公司 | 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN104774860B (zh) | 2018-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shen et al. | Development of CRISPR/Cas9 for efficient genome editing in Toxoplasma gondii | |
EP3105328B1 (en) | Crispr enabled multiplexed genome engineering | |
CN105132451B (zh) | 一种CRISPR/Cas9单一转录单元定向修饰骨架载体及其应用 | |
CN109136248B (zh) | 多靶点编辑载体及其构建方法和应用 | |
CN107488649A (zh) | 一种Cpf1和p300核心结构域的融合蛋白、相应的DNA靶向激活系统和应用 | |
CN109880851B (zh) | 用于富集CRISPR/Cas9介导的同源重组修复细胞的筛选报告载体及筛选方法 | |
CN106795521A (zh) | 用于修饰所靶向基因座的方法和组合物 | |
CN107365786A (zh) | 一种将spacer序列克隆至CRISPR-Cas9系统中的方法及其应用 | |
CN105821075A (zh) | 一种茶树咖啡因合成酶CRISPR/Cas9基因组编辑载体的构建方法 | |
CN105695485A (zh) | 一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用 | |
Malina et al. | Adapting CRISPR/Cas9 for functional genomics screens | |
US4687737A (en) | Mammalian suppressor genes | |
CN106434701B (zh) | 鸭疫里默氏杆菌的rpsL突变基因及其应用 | |
CN104774860A (zh) | 适于转化细胞的构建体、系统及其应用 | |
WO2023028348A1 (en) | Enzymes with ruvc domains | |
US20230159958A1 (en) | Methods for targeted integration | |
CN111705072B (zh) | 利用重组酶调控基因表达的方法 | |
CN111662932B (zh) | 一种提高CRISPR-Cas9基因编辑中同源重组修复效率的方法 | |
CN111549070B (zh) | 对x染色体多拷贝基因进行编辑实现动物性别控制的方法 | |
GB2507030A (en) | Algal genome modification | |
CN113151277A (zh) | 鸡DF-1细胞IHH基因敲除稳定细胞株的构建方法及其特异性sgRNA | |
CN114891791B (zh) | 特异性靶向犬Rosa26基因的sgRNA及其应用 | |
KR20200026164A (ko) | 세포의 유전체에서 표적 핵산을 변형시키는 방법 | |
CN105331601B (zh) | 一种基于自然转化的副猪嗜血杆菌高效遗传重组方法及应用 | |
CN111349616A (zh) | 一种筛选目标病毒相关宿主因子的方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 518083 Yantian District, Yantian District, Shenzhen, Guangdong. Applicant after: BGI SHENZHEN Applicant after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 comprehensive building, Beishan Industrial Zone, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Applicant before: SHENZHEN BGI AGRICULTURE AND CYCLE ECONOMIC TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191213 Address after: 518120 A205, Peng Fei Road, Dapeng street, Dapeng New District, Shenzhen, Guangdong, China, 7 Patentee after: Shenzhen Huada Gene Agriculture Holding Co.,Ltd. Address before: 518083 Complex Building of Beishan Industrial Zone, Yantian Street, Yantian District, Shenzhen City, Guangdong Province Co-patentee before: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Patentee before: BGI SHENZHEN |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180717 |